EMA panel adopts positive opinion of Vemlidy for treatment of HBV in adults, adolescents

Vemlidy, a drug to treat chronic HBV patients, has receive positive opinion from the EMA’s Committee for Medicinal Products for Human Use. Patients only require a 25mg dose of this powerful medicine, in which is less than 1/10th the amount of another well-known medication.

Learn more all about it here: bit.ly/2frS6yf

1 Reply

oldestnewest
  • This is all good in the UK we sat in the meetings to ok this drug and its trials are great like for like better especially for those with bone density calcium and vit d issues